
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Beam is seeking a highly motivated and strategic Associate Director, Investor Relations to join our growing Investor Relations and External Communications team at a pivotal moment in the company's evolution. In this role, you will support the execution of Beam's investor relations strategy and play a central part in shaping how Beam's science, pipeline, and corporate narrative are communicated to the investment community. You will partner closely with senior leadership, finance, legal, corporate communications, and program teams to translate complex clinical and scientific milestones into clear, compelling, investor-ready messaging across earnings cycles, conferences, and one-on-one engagements. This position is critical to building a best-in-class IR function as Beam transitions from a clinical-stage to commercial-stage biotechnology company delivering on the promise of base editing for patients with serious diseases.
Key Responsibilities:
Required Qualifications:
Preferred Qualifications:
The salary range below reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on several factors including, but not limited to, relevant experience, education, scope of job, internal comparisons, and market data.

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes.
Our dream is to provide life-long cures for patients suffering from serious diseases.
The Beam Team Is:
• A community of fearless innovators
• Rigorous and honest in our research
• Listening with open minds
• Committed to each other